Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tecentriq Fails to Improve PFS in Ovarian Cancer: Roche/Chugai
July 14, 2020
- Treakisym Filed for Triple Therapy in DLBCL
July 14, 2020
- 23 Drug Makers to Invest US$1 Billion in “AMR Action Fund” to Develop 2-4 New Antibiotics by 2030
July 14, 2020
- Takeda Looks to Derive 70%-Plus of Japan Sales from 5 Focus Areas by FY2025, Revamp HR Systems
July 13, 2020
- Eisai Joins Forces with Four Universities on R&D of Lupus Drug
July 13, 2020
- Bayer Revving Up Cell Therapy Drive with First Focus on Parkinson’s, Japan Biz Also Eyed: R&D Chief
July 10, 2020
- Yoshiaki Aono to Be Promoted to Chairman and President of Nippon BI in September
July 10, 2020
- Maruho’s Nemolizumab Hits Primary Goal in Japanese PIII for Itching in Atopic Dermatitis
July 10, 2020
- Xofluza Effective for Post-Exposure Prophylaxis of Influenza: Japan PIII
July 10, 2020
- Astex’s Inqovi Gets Approval in US, Canada: Otsuka
July 9, 2020
- Eisai Files Tazemetostat for Follicular Lymphoma in Japan
July 9, 2020
- Eisai’s Sleep Inducer Dayvigo Accepted in Hong Kong
July 9, 2020
- Lenvima-Keytruda Combo’s 1st Line HCC Bid Nixed in US after Rival Nod
July 9, 2020
- Patient Numbers Remain Down at Over 60% of Hospitals Even after Emergency Lifted: Survey
July 9, 2020
- Aducanumab Filing Completed in US; Talks with Japan/EU Regulators Ongoing
July 9, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- GSK in Quest for Best COVID-19 Vaccine, Not the First: Japan Chief Lirette
July 8, 2020
- Sales Rep Promotions in May Tank 67% YOY: Intage
July 8, 2020
- Japan Ethical Drug Sales Slide 12.0% in May: Crecon
July 8, 2020
- EU Regulators Accept Enhertu for Accelerated Review for HER2-Positive Breast Cancer
July 8, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…